Blue Horizon International AG was formed in 2017 to commercialize stem cell technology and regenerative medicine. It operates clinics in Slovakia, Jamaica, and China where it has successfully treated over 600 patients for conditions like spinal cord injury, cerebral palsy, and stroke. The company projects rapid revenue growth from $851k in 2020 to over $310 million in 2024 as it expands globally based on the large and growing market opportunity for stem cell therapies in areas like stroke and Alzheimer's disease that affect millions worldwide.
L20 Financial issues in healthcare: Ethical and Legal IssuesDr Ghaiath Hussein
This lecture is based on the Saudi Code of Ethics regarding the ethical and legal aspects related to the financial issues in health care, namely: Healthcare Practitioner’s Fee, Practicing in Private Sector, Participation in the Media, Gifts and Benefits, and the Relationships with Pharmaceutical and Medical Equipment and Companies.
This was presented to Alfarabi Medical College level 5 students as part of the Medical Ethics & Professionalism Course (30-4-2017)
L20 Financial issues in healthcare: Ethical and Legal IssuesDr Ghaiath Hussein
This lecture is based on the Saudi Code of Ethics regarding the ethical and legal aspects related to the financial issues in health care, namely: Healthcare Practitioner’s Fee, Practicing in Private Sector, Participation in the Media, Gifts and Benefits, and the Relationships with Pharmaceutical and Medical Equipment and Companies.
This was presented to Alfarabi Medical College level 5 students as part of the Medical Ethics & Professionalism Course (30-4-2017)
Tiziana Life Sciences is a dual-listed clinical stage biotechnology company focused on the discovery and development of novel molecules to treat human disease in oncology and immunology. Tiziana’s two lead drug candidates, Foralumab and Milciclib, uniquely target the root cause of diseases with large unmet needs in multibillion-dollar markets. Tiziana is accelerating development of anti-IL6 receptor monoclonal antibody (mAb) for treatment of COVID-19 lung inflammation. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. Tiziana is a market leader in the invention of proprietary technology for oral, nasal and inhaled formulation to transform immunotherapies with Monoclonal Antibodies currently administered intravenously. Also, Tiziana has a robust and growing patent portfolio.
The Patient-Centered Clinical Trial: A New ParadigmJohn Reites
Patient centricity is no longer just viewed as an opportunity
solely for commercial pharma. In September 2014,
eyeforpharma brought together 100 US clinical leaders
to discuss the evolving role of patients in clinical trials.
The executive forum addressed the latest trends and
innovations in clinical trial management from a patientcentric
perspective, but it was the presence and involvement
of several patients and patient advocates that shaped the
discussion and expanded our thinking on the topic. Beyond
debating various practical questions, delegates from
pharma began to wonder how the necessary changes might
materialize under the organizational lens.
Transform Your Career with a Fellowship in Reproductive MedicineIVF Treatment
Embarking on the journey of parenthood is a significant milestone for many individuals and couples. However, reproductive challenges can arise, leading to the need for specialized medical assistance. In such cases, the field of reproductive medicine offers hope and innovative solutions. Among the various educational and training programs available for healthcare professionals, a Fellowship in Reproductive Medicine stands out as a valuable opportunity to gain expertise in this evolving field. This article explores the significance, benefits, and career prospects associated with pursuing a Fellowship in Reproductive Medicine.
Tiziana Life Sciences (NASDAQ: TLSA) Investor Presentation - July 20th 2020RedChip Companies, Inc.
Tiziana Life Sciences (NASDAQ: TLSA) is a dual-listed clinical stage company developing targeted therapeutics to transform treatment of liver diseases, inflammatory diseases, and cancer. Our clinical pipeline includes drug assets for Crohn's, and hepatocellular carcinoma. Tiziana’s two lead drug candidates, Foralumab and Milciclib, uniquely target the root cause of diseases with large unmet needs in multibillion-dollar markets. Tiziana is accelerating development of anti-IL6 receptor monoclonal antibody (mAb) for treatment of COVID-19 lung inflammation. Tiziana is a market leader in the invention of proprietary technology for oral, nasal and inhaled formulation to transform immunotherapies with Monoclonal Antibodies currently administered intravenously. Also, Tiziana has a robust and growing patent portfolio.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, tissues, and living cells for their research, with the available biospecimens. Its iSpecimen Marketplace platform solves this problem and transforms the biospecimen procurement process to accelerate medical discovery.
Tiziana Life Sciences (NASDAQ: TLSA) is a dual-listed clinical stage company developing targeted therapeutics to transform treatment of liver diseases, inflammatory diseases, and cancer. Our clinical pipeline includes drug assets for Crohn's, and hepatocellular carcinoma. Tiziana’s two lead drug candidates, Foralumab and Milciclib, uniquely target the root cause of diseases with large unmet needs in multibillion-dollar markets. Tiziana is accelerating development of anti-IL6 receptor monoclonal antibody (mAb) for treatment of COVID-19 lung inflammation. Tiziana is a market leader in the invention of proprietary technology for oral, nasal and inhaled formulation to transform immunotherapies with Monoclonal Antibodies currently administered intravenously. Also, Tiziana has a robust and growing patent portfolio.
Liberty Health Sciences Investor Relations Deck for FY2021-August. For more information on our company and products, please visit us at www.libertyhealthsciences.com.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Tiziana Life Sciences is a dual-listed clinical stage biotechnology company focused on the discovery and development of novel molecules to treat human disease in oncology and immunology. Tiziana’s two lead drug candidates, Foralumab and Milciclib, uniquely target the root cause of diseases with large unmet needs in multibillion-dollar markets. Tiziana is accelerating development of anti-IL6 receptor monoclonal antibody (mAb) for treatment of COVID-19 lung inflammation. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. Tiziana is a market leader in the invention of proprietary technology for oral, nasal and inhaled formulation to transform immunotherapies with Monoclonal Antibodies currently administered intravenously. Also, Tiziana has a robust and growing patent portfolio.
The Patient-Centered Clinical Trial: A New ParadigmJohn Reites
Patient centricity is no longer just viewed as an opportunity
solely for commercial pharma. In September 2014,
eyeforpharma brought together 100 US clinical leaders
to discuss the evolving role of patients in clinical trials.
The executive forum addressed the latest trends and
innovations in clinical trial management from a patientcentric
perspective, but it was the presence and involvement
of several patients and patient advocates that shaped the
discussion and expanded our thinking on the topic. Beyond
debating various practical questions, delegates from
pharma began to wonder how the necessary changes might
materialize under the organizational lens.
Transform Your Career with a Fellowship in Reproductive MedicineIVF Treatment
Embarking on the journey of parenthood is a significant milestone for many individuals and couples. However, reproductive challenges can arise, leading to the need for specialized medical assistance. In such cases, the field of reproductive medicine offers hope and innovative solutions. Among the various educational and training programs available for healthcare professionals, a Fellowship in Reproductive Medicine stands out as a valuable opportunity to gain expertise in this evolving field. This article explores the significance, benefits, and career prospects associated with pursuing a Fellowship in Reproductive Medicine.
Tiziana Life Sciences (NASDAQ: TLSA) Investor Presentation - July 20th 2020RedChip Companies, Inc.
Tiziana Life Sciences (NASDAQ: TLSA) is a dual-listed clinical stage company developing targeted therapeutics to transform treatment of liver diseases, inflammatory diseases, and cancer. Our clinical pipeline includes drug assets for Crohn's, and hepatocellular carcinoma. Tiziana’s two lead drug candidates, Foralumab and Milciclib, uniquely target the root cause of diseases with large unmet needs in multibillion-dollar markets. Tiziana is accelerating development of anti-IL6 receptor monoclonal antibody (mAb) for treatment of COVID-19 lung inflammation. Tiziana is a market leader in the invention of proprietary technology for oral, nasal and inhaled formulation to transform immunotherapies with Monoclonal Antibodies currently administered intravenously. Also, Tiziana has a robust and growing patent portfolio.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, tissues, and living cells for their research, with the available biospecimens. Its iSpecimen Marketplace platform solves this problem and transforms the biospecimen procurement process to accelerate medical discovery.
Tiziana Life Sciences (NASDAQ: TLSA) is a dual-listed clinical stage company developing targeted therapeutics to transform treatment of liver diseases, inflammatory diseases, and cancer. Our clinical pipeline includes drug assets for Crohn's, and hepatocellular carcinoma. Tiziana’s two lead drug candidates, Foralumab and Milciclib, uniquely target the root cause of diseases with large unmet needs in multibillion-dollar markets. Tiziana is accelerating development of anti-IL6 receptor monoclonal antibody (mAb) for treatment of COVID-19 lung inflammation. Tiziana is a market leader in the invention of proprietary technology for oral, nasal and inhaled formulation to transform immunotherapies with Monoclonal Antibodies currently administered intravenously. Also, Tiziana has a robust and growing patent portfolio.
Liberty Health Sciences Investor Relations Deck for FY2021-August. For more information on our company and products, please visit us at www.libertyhealthsciences.com.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
Best Ayurvedic medicine for Gas and IndigestionSwastikAyurveda
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Colonic and anorectal physiology with surgical implications
BHI Corporate Overview March 2020
1. For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
0
Corporate Overview
March 2020
2. 1
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Private Company Disclosure
This Confidential Investor Presentation (the ‘Presentation Is being delivered to a select number of parties who have expressed an interest in
pursuing a business or financial relationship with Blue Horizon International AG. Nothing contained within this Presentation alone is an offer
to buy or sell securities or an offering of any product, service or fund. An offer to buy or sell securities will only be accompanied by appropriate
documents including, but not limited to, a private placement memorandum or Offering Circular which will contain, among other things, a
listing of possible risk factors associated with the securities being offered. All representations and warranties are hereby disclaimed. The
Information contained in this presentation is intended for general Informational purposes only and is not Intended to be information sufficient
for the making of a business or investment decision. While reasonable efforts have been made to ensure that the information contained in this
Presentation has been obtained from sources deemed to be reliable, Blue Horizon International AG does not guaranty that the information
contained herein is accurate or complete and is not responsible for any errors or omissions, or for the results obtained from the use of this
information. All information in this Presentation is provided “as is” with no guarantee of completeness, accuracy, timeliness or of the results
obtained from the use of this Information, and without warranty or representation of any kind, statutory, express, or implied, oral or written. In
no event will Blue Horizon International AG, its related entities, or its members, partners, agents or employees be liable to you or anyone else
for any decision made or action taken in reliance on the information in this Presentation alone or for any consequential, special or similar
damages, even if advised of the possibility of such damages. You should conduct your own due diligence with respect to any and all information
related to this document and the offering in the private placement memorandum or Offering Circular and are not entitled to rely solely on the
information in this Presentation. Further, Blue Horizon International AG is under no obligation to update the material or information
presented herein even if they later become aware that such information or material is no longer accurate or true. Any recipient of this
Presentation assumes all risk in, and Blue Horizon International AG will not be liable for any damages arising out of, use of information
including. without limitation, business decisions made or inferences drawn by anyone in reliance on the Presentation at the fact of the disclosure
of the information. All communications or inquiries relating to Blue Horizon International AG should be directed to Brian Mehling at 866-263-
2479 or by email to mehling@rcn.com.
3. 2
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Table of Contents
1. Corporate Overview
2. Markets & Opportunities
3. Safety & Research
Information
4. BHI Charitable
Foundation & Patient
Testimonials
5. US Affiliate Company,
BHI Therapeutic
Sciences
Introduction to BHI and Dr. Brian Mehling
Outline of the opportunities for stem cell treatment and
medical truism
Walkthrough of several BHI conducted studies that
provide information on the safety and therapeutic effects
of stem cell treatments on patients
Overview of BHI’s expansion into the US Market
Insight into multiple success stories from patients of BHI’s
procedures and the company’s ongoing efforts to bring
affordable stem cell treatments to the broader public
4. 3
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Corporate Overview
Introduction to BHI and Dr. Brian Mehling
1. Corporate Overview
5. 4
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Blue Horizon: Corporate Overview
Blue Horizon
International AG
was formed in 2017
to monetize stem
cell technology
and associated
regenerative medicine
Blue Horizon is focused on using stem cells to treat a wide
range of diseases and to provide health benefits without the
use of drugs or surgery.
The company has an established manufacturing process for
the necessary supply of stem cells and understands the
treatment procedures via its clinical practices.
6. 5
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Founder Dr. Brian Mehling MD, MS
Dr. Brian Mehling, MD, MS
Founder & Chief Medical Officer
Brian Mehling, M.D., M.S. is the founder and chief medical officer of Blue Horizon International
(BHI). He is a practicing American orthopedic trauma surgeon, researcher, and philanthropist.
Dr. Mehling started his path in medicine through undergraduate study at Harvard University,
obtaining his Bachelor of Arts and Master of Science degrees in Biochemistry from Ohio State
University. Completing his degree of medicine at Wright State University School of Medicine, Dr.
Mehling received post graduate education through residencies and fellowships at St. Joseph’s
Hospital in Paterson, NJ and the Graduate Hospital in Philadelphia, PA, while pursuing a Ph.D. in
Chemistry.
Educational Background
Dr. Mehling has traveled extensively throughout Asia and the Middle East observing firsthand the
differences in healthcare standards. Identifying the need for a universal high quality standard, he
founded Blue Horizon International.
Global Perspective
Dr. Mehling founded the Blue Horizon Charitable Foundation, which was with the mission to assist
in and finance the advancement of all aspects of stem cell therapies and cellular regenerative
medicine and research in full regulatory conformance, in conjunction with the scientific community.
The foundation will also support and provide charitable therapies to those suffering from
degenerative diseases and debilitating conditions.
He and his colleagues have successfully treated and monitored more than 600 patients using stem cell
and regenerative therapies. Patients have been treated for a wide range of diseases and disorders
including spinal cord injury and cerebral palsy.
Stem Cell Pioneer
Charitable Founder
7. 6
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Founder, Chief Medical Officer, MD, MS
Internationally known, board-certified orthopedic
trauma surgeon
Operates own practice, Mehling Orthopedics, in West
Islip, NY and Hackensack, NJ
Undergone 30+ stem cell therapies himself in the last
7 years
Harvard University undergraduate
Chief Executive Officer
23 years of experience in healthcare management
Served as Senior Vice President of Operations at
Hackensack University Medical Center
Registered nurse with a Masters of Science degree in
Health Administration
Chief Financial Officer
Over 30 years of experience in accounting and finance
Spent 16 years as a CFO
Chief Science Officer, MD, PhD
Professor at Wuhan University School of Basic Medical
Science
Chu Tian Scholar
Leading expert in stem cell mechanics
Focus on designing clinical trials using stem cells to treat
spinal cord injury
Director of Cultural Relations
Guides Blue Horizon’s community and stakeholder
relationships
Serves as chairman of the unaffiliated not-for-profit
company, Blue Horizon Charitable Foundation
Clinical Research Scientist
Doctor of Philosophy (PhD) in Biological Sciences
Postdoctoral education at the Institute of Human Genetics,
University Hospital Jena, Germany
Fifteen years of experience in biomedical research, five years
of experience in clinical research
Author of over 40 research papers in peer-reviewed journals
Dr. Brian Mehling
Dr. Dongcheng Wu
Doreen Santora
Eddie Amarante
John Pape
Marine
Manvelyan
Successfully treated and monitored 600+ subjects
using stem cell therapies
Katarina
Novokova
President, BHI Slovakia
Oversees Blue Horizon’s operations in Slovakia
Director of relations od Blue Horizon Charitable
Foundation
Nominee for the Economic World Forum’s Young
Global Leaders (Class of 2019) Klara Doert
President, Business Development
Oversees Blue Horizon’s Stem Cell and Skin Care business
development
20 years of leadership experience in cosmeceuticals, spa, medical
spa, and alternative therapy industries in Europe, the United
States of America, and Asia.
Director of the Global Healthcare Forum of Diplomatic Council
Leadership Team
8. 7
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Scientific Advisory Board
Cognitive neuroscientist and entrepreneur
affiliated with Harlem Biospace, the first
biotechnology startup incubator in New York City
Founding director of the biomedical accelerator
facility at Mount Sinai School of Medicine, NY
Medical Professor at the Sophie Davis Medical
SchoolAndre Ragnauth, Ph.D.
Professor at Wuhan University School of Basic
Medical Science
Chu Tian Scholar
Leading expert in stem cell mechanics
Focus on designing clinical trials using stem cells
to treat spinal cord injury
Chief Science Officer of Blue Horizon
Dongcheng Wu,
M.D., Ph.D.
James S. Riepe University Professor;
Department of Neuroscience
Perelman School of Medicine; Department of
Psychology, School of Arts and Sciences
Marketing Department, The Wharton School,
University of PennsylvaniaMichael Platt, M.D.
Cancer scientist at the Keck School of Medicine
of USC in Los Angeles, California
Specialized in neurodevelopment, cell signaling,
cancer stem cell, pre-clinical development, and
molecular targeted therapy for cancer treatment.
Ph.D., Keck School of Medicine of USC
B.S., B.A., Mount Saint Mary’s College
Vicky Yamamoto, Ph.D.
Jason Dictenberg, PhD
CEO and Chief Scientist, AccelBio LLC
Research Associate Professor, SUNY Downstate
Medical Center
Ph.D., Molecular Medicine, University of
Massachusetts Medical School/Harvard Medical
School
B.A., Molecular Biology and Genetics, Highest
Honors in Research, Brandeis University
Joseph Feldman, M.D.
Board-certified emergency medicine physician
in NY and NJ
Current medical director at Mount Sinai
Urgent Care and former chairman of the
Emergency/Trauma Center at Hackensack
University Medical Center
Author of several publications and books.
Michael A. Kelly, M.D.
Chairman, Department of Orthopaedic Surgery,
Hackensack University Medical Center
Past President, American Knee Society
Former Team Physician, NBA’s NJ Nets
Lectures extensively throughout the US and
internationally
Practicing dentist lecturer, author, and developer
of nutraceuticals
Holistic dentist
Keynote Speaker, Anti-Aging Medicine
Specialization in Europe
Head of the FirstBioDentSpa ClinicHansjorg Lammers,
DMD, Ph.D.
9. 8
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
An Expanding Global Presence
Slovakia
100% BHI owned clinic
$5,000 charge per treatment
Located on the outskirts of Bratislava
Jamaica
65% BHI owned clinic
Jamaica is the largest English-speaking Caribbean
Island
Positioned to take advantage of medical tourism
Typically $5,000 per therapy
GMP-certified facility
US board-certified physicians on staff
Wuhan, China
More than 3,000 patients have been successfully
treated in the Stem Cells Therapy Center at Wuhan
Hong Qiao Brain Hospital
Treatments have focused on spinal cord injury, brain
trauma, stroke, cerebral palsy, brain disease,
encephalitis, and several kinds of nervous
degenerative diseases
Global clinics operating (outside United States):
Blue Horizon aims to launch more
100% owned locations as well as
additional partnerships
10. 9
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Historical Start-up & Test Phase Revenues
Notes to Historical Revenues
Early years include only revenues
from payments received
Company benefited from patients
that participated in early procedures –
even if payment was never received
by patient and/or insurance company
Company/affiliates have preformed
over 700 procedures
Growth phase to commence upon
completion of 1Q2020 capital raise
* Estimate
11. 10
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Financial Projections
1
Based on estimated corporate tax rate and customary treatment of tax-loss carryforward
2
EBITDA is not generally considered GAAP accounting
Note: Projections are dependent upon reasonably timed funding, relate to future performance, and reflect expectations at the time
this presentation was prepared and are subject to risks, uncertainties and assumptions that may cause these projections
to differ materially from actual results. We can provide no assurance that these expectations will prove to be correct and
these financial projections should not be unduly relied upon.
Blue Horizon International AG 2020 2021 2022 2023 2024
(Projected) (Projected) (Projected) (Projected) (Projected)
Revenue 851,219$ 11,390,741$ 59,295,448$ 157,963,173$ 310,693,592$
Costs & Expenses
Cost of Goods Sold 374,536$ 5,011,926$ 26,089,997$ 69,503,796$ 136,705,181$
General & Administrative 406,913$ 2,060,704$ 5,221,260$ 10,061,849$ 16,746,302$
Marketing 401,582$ 1,956,210$ 4,765,793$ 8,838,692$ 14,157,722$
Depreciation & Amortization 27,189$ 169,768$ 358,476$ 555,100$ 732,786$
R&D 129,304$ 157,170$ 191,041$ 232,211$ 282,254$
Total Cost & Expenses 1,339,524$ 9,355,779$ 36,626,567$ 89,191,648$ 168,624,245$
Income from Operation (488,305)$ 2,034,963$ 22,668,882$ 68,771,525$ 142,069,347$
Pre-tax Income (488,305)$ 2,034,963$ 22,668,882$ 68,771,525$ 142,069,347$
Provision for Income Tax1
-$ 433,064$ 6,347,287$ 19,256,027$ 39,779,417$
Net Income (488,305)$ 1,601,898$ 16,321,595$ 49,515,498$ 102,289,930$
EBITDA
2
(461,116)$ 2,204,731$ 23,027,358$ 69,326,625$ 142,802,133$
12. 11
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Financial Projections For Additional Single Clinic
Financial Projections
Year One
(Projected)
Year Two
(Projected)
Year Three
(Projected)
Year Four
(Projected)
Year Five
(Projected)
Number of Patients 100 200 400 800 1600
Gross Stem Cell Revenue $ 500,000 $ 1,000,000 $ 2,000,000 $ 4,000,000 $ 8,000,000
Net Profit Before Tax $100 Repayed to Hospital $ 250,000 $ 600,000 $ 1,400,000 $ 3,200,000
Hospital Share Before Tax No Effective Net Profit $ 104,500 $ 250,800 $ 585,200 $ 1,337,600
Estimated Ancillary Services $ 50,000 $ 100,000 $ 200,000 $ 400,000 $ 800,000
1Based on estimated corporate tax rate
and customary treatment of tax-loss
carry forward
2EBITDA is not generally considered
GAAP accounting
Note: Projections are dependent upon
reasonably timed funding, relate to
future performance, and reflect
expectations at the time this
presentation was prepared. Projections
are subject to risks, uncertainties, and
assumptions that may cause these
projections to differ materially from the
actual results. We can provide no
assurance that these expectations will
prove to be correct and these financial
projections should not be unduly relied
upon.
13. 12
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Markets & Opportunities
Outline of the opportunities for stem cell treatment
and medical tourism
2. Markets & Opportunities
14. 13
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Stem Cell Market Opportunity
Blue Horizon is
working to bring the
miracle of life saving
stem cell treatments
to the world
We address widespread medical conditions, including…
(1) According to the US Centers for Disease Control and Prevention and the World Health Organization
(2) According to the Alzheimer's Association and Alzheimer's Disease International
15 million people suffer a stroke each year worldwide. In the United States,
nearly 800,000 people suffer from a stroke annually, making it the leading
cause of serious, long term disability in the US and the United Kingdom(1)
An estimated 50 million people, including 5.5 million Americans, suffer from
Alzheimer’s and other related dementias(2)
422 million people worldwide, including 29 million Americans, have diabetes,
with another estimated 8.1 million Americans undiagnosed, living unaware of
their condition(1)
7.2 million people worldwide, including 610,000 Americans, die each year
from heart disease(1)
54.4 million people in the U.S suffer from arthritis(1)
Stroke
Alzheimer’s Disease
Heart Disease
Arthritis
Diabetes
15. 14
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
About Stem Cells
Stem cells have the remarkable potential
to develop into many different cell types
in the body. They can be used to
regenerate the human body without
drugs or surgery
Treatment initiated over 50 years ago
Originated from bone marrow transfers
Stem cells regularly divide to repair and replace worn out or damaged
tissue
Due to legal and ethical issues of using embryonic cells, Blue Horizon
uses placenta cord tissue from healthy babies – without any injury to
baby or mother
Other source of stem cells is from patients themselves
Origin of Stem Cells
Retrospective chart review studies of human umbilical cord blood derived
mononuclear cell therapy in subjects with spinal cord injury, stroke, and chronic
inflammation
Retrospective chart review study of human adipose tissue derived mononuclear
cell therapy in subjects with musculoskeletal conditions
Safety study of allogeneic cord blood hematopoietic progenitor cell therapy of
subjects with chronic inflammation (not yet initiated)
Research Studies in Regenerative Medicine
Bring down long term medical costs
Alleviate Suffering
Potential to repair damage on all parts of body which have not yet been repaired
No medication required- holistic approach
Overall advantages of stem cells
16. 15
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Stem Cell Extraction Methods
Umbilical Cord Blood (UCB)
Rich source of hematopoietic stem cells and progenitor cells as well as non-hematopoietic stem cells
Can be directly used after isolation without expansion
The human leukocyte antigen type does not need a closely matched donor for non-hematopoietic
purposes as these cells are less likely to induce immunological reactions
Autologus Stem Cells
Removal of adipose tissue under local anesthesia
Lipoaspirate after extraction
Isolation of stromal vascular fraction with MSCs
Preparation ready for administration
Administration of preparation into the hip or knee joint
Wharton’s Jelly (WJ)
Expanded MSCs from WJ of healthy donors who underwent elective full-term pregnancy caesarean
sections
Umbilical Cord is collected from primiparous pregnant women receiving caesarean section in
accordance with the sterile procedure guidelines in each hospital– no injury to the baby or mother
Treatment Modalities
Intravenous infusion for peripheral injury or disease
Intrathecal injection – for central nervous system pathology
Intra-articular injection – for joint pathology
17. 16
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Global Medical Tourism Market Opportunity
Blue Horizon is
poised to capture not
only the opportunities
in the stem cell arena,
but will also be
positively impacted by
tremendous growth of
the global medical
tourism industry
*Statics are according to Patients Beyond Boards. www.patientsbeyondborders.com
Global Medical Tourism market size is estimated to be USD
65-87.5 billion, based on approximately 20-24 million cross-
border patients worldwide spending an average of USD $3410
per visit
With the world population aging and becoming more affluent at
rates that surpass the availability of quality healthcare resources,
it is anticipated that the market will growth at a rate of 15-25%
annually
It is projected that some 2.2 million Americans will travel
outside the US for medical care this year (2020), where
projected savings are estimated to be in the 30 to 60 percent
range for the top destinations
18. 17
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Safety & Research Information
Walkthrough of several BHI conducted studies that provide
information on the safety and therapeutic effects of stem cell
treatments on patients
3. Safety & Research Information
19. 18
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Safety of BHI Stem Cell Therapy
• BHI has taken every precaution to ensure the safety and
viability of their stem cell treatments, having successfully
treated more than 600 patients and documenting each
procedure.
• The long-term safety study results of human allogeneic
umbilical cord blood, tissue, and autologous bone marrow
cell therapy indicate that 29 subjects with chronic
inflammation did not develop serious medical conditions
related to stem cell therapy 4-7 years after administration.
• Research published in “Experimental and therapeutic
medicine” cited at PubMed Central, US National Library
of Medicine, National Institutes of Health; “CellR4”, the
official journal of The Cure Alliance; and presented at the
American Academy of Orthopedic Surgeons.
• Stem cells evaluated in clinical studies are collected in
accordance with Good Tissue Practice to ensure safety
and have been approved by the Investigational Research
Board and in accordance with Good Clinical Practice.
20. 19
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Retrospective cohort study for Spinal Cord Injury (SCI) subjects
Analyze muscle, nerve, urinary, and gastrointestinal functions
in SCI subjects treated with human Umbilical Cord Blood
Mononuclear Cells (hUCB-MNCs) versus conventional
therapy
Goal
-30 subjects with SCI were randomly selected from 70
treated with hUCMNCs between March 2009 and March
2012 in Wuhan Hongqiao Brain Hospital, a longtime BHI
partner, and using BHI’s stem cell treatment procedures.
-Another 30 subjects with SCI received only traditional
therapy and no stem cell therapy
Subjects and Location
- Approved by the Institutional Review Board (Office of
Research and Sponsored Programs. SC#5488, April 2, 2014).
- Results published in peer-reviewed journal, CellR4, in 2018
Approval and publications
0
5
10
15
20
25
30
Pre Post Pre Post
NumberofSubjects
None Normal
Stem Cell Therapy Traditional Therapy Only
Changes in ability to sense pain
0
5
10
15
20
25
30
Pre Post Pre Post
NumberofSubjects
None Normal
Traditional TherapyStem Cell Therapy
Changes in ability to sense temperature
Results
21. 20
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Retrospective cohort study for Spinal Cord Injury (SCI) subjects (Continued)
0
5
10
15
20
25
30
35
Pre Post Pre Post
NumberpfSubjects
LLM=0 LLM=1 LLM=2
Stem Cell Therapy Traditional Therapy Only
Results (cont.)
Changes in lower limb muscle (LLM) strength*
0
5
10
15
20
25
30
35
Pre Post Pre Post
NumberofSubjects
Incontinence Catheterization Normal
Stem Cell Therapy Traditional Therapy Only
Changes in bladder function
A significantly higher proportion of subjects in the stem cell therapy group showed improved function in pain and
temperature sensation, lower limb muscle strength, and bladder function, compared to the conventional therapy group.
* Utilized a non-traditional quantitative scoring system for strength
22. 21
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Retrospective cohort study for stroke subjects
Analyze impact of human Umbilical Cord Blood
Mononuclear Cells (hUCB-MNC) therapy on mobility and
muscle strength of upper and lower extremities, and
neurological function in subjects with ischemic and
hemorrhagic stroke.
Goal
97 subjects with ischemic and hemorrhagic stroke were
treated with human Umbilical Cord Blood Mononuclear
Cells (hUCB-MNCs) between March 2009 and March 2012
in Wuhan Hongqiao Brain Hospital, a longtime BHI partner,
and using BHI’s stem cell treatment procedures.
Subjects and Location
- Approved by Institutional Review Board (IRCM-2017-135,
January 18, 2017).
- Results are presented at the conference Adult Stem Cells
and Regenerative Medicine. The New York Academy of
Sciences, NY, 2019.
Approval and publications
Results
0%
20%
40%
60%
80%
100%
1 2 3 4 5 6
Physical conditions
Percentage of improvement*
* Percentage of aubjects that reported post-treatment improvement of the
following conditions after having reported suffering from such conditions prior
to treatment
1. Upper extremity mobility
2. Lower extremity mobility
3. Neurological function (ability to speak)
4. Upper extremity muscle strength
5. Lower extremity muscle strength
6. Neurological function (urinary and bowel function)
23. 22
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Retrospective cohort study for arthritis subjects
Analyze changes in pain and mobility of research subjects
with osteoarthritis and rheumatoid arthritis after receiving
treatment with stem cells derived from adipose tissue.
Goal
350 subjects underwent the therapy with their own cells at
the Malacky Hospital in Bratislava, Slovakia, a partner of a
BHI affiliate
Subjects and Location
-Study was approved by the Ministry of Health of the Slovak Republic and by the Institutional Review Board (IRCM-2017-137, January
18, 2017)
- Results are presented at the American Academy of Orthopedic Surgeons Annual Meeting, New Orleans, Louisiana, 2018
Approval and publications
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
7 days 3
months
6
months
12
months
Decrease
No Change
Increase
Changes in Pain after Therapy
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
7 days 3
months
6
months
12
months
Increase
No Change
Decrease
Changes in Mobility after Therapy
Results: Significant decrease in subjects’ pain sensation and improvement in subjects’ mobility were observed three,
six and 12 months comparing to seven days after therapy
24. 23
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Retrospective chart review study for subjects with chronic inflammation
Evaluate the safety of Human Cord Blood Derived
Mononuclear Cell (hUCBMC) therapy for subjects with
chronic inflammation and the effects on different health
indicators
Goal
30 research subjects received hUCBMC therapy in the period
2010-2013 in Hackensack, New Jersey under the direct purview
of BHI
Subjects and Location
- Study was approved by the Institutional Review Board (IRCM 2014-040, December 17, 2014)
- Results published in peer-reviewed journal CellR4 in 2015
Approval and publications
Changes in Pain after Therapy
Results
0
10
20
30
40
50
60
70
80
90
100
Energy/fatigue Social
functioning
Pain General Health
Initial
3 months
6 months
Notes:
- A higher pain level indicator implies less physical
pain, and vice versa.
- Data indicate continued improvement over six
month period
- Preliminary results of blood test markers indicate
that research subjects did not develop any adverse
effects or adverse medical conditions over the six
month period
25. 24
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
BHI Charitable Foundation & Patient
Testimonials
Insight into multiple success stories from patients of BHI’s
procedures and the company’s ongoing efforts to bring
affordable stem cell treatments to the broader public
4. BHI Charitable Foundation & Patient Testimonials
26. 25
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
BHI Charitable Foundation
The Blue Horizon
Charitable Foundation
was formed with the
mission to assist in and
finance the
advancement of all
aspects of stem cell
therapies and cellular
regenerative medicine.
Dedicated to increasing the awareness of global inequalities in
healthcare, as well as providing charitable medical care and
education to adults and children in impoverished areas.
Raises capital in order to support medical centers and clinics
by providing medicines vital to basic human survival, by
performing advanced medical treatments otherwise not
accessible to certain geographic regions.
Produces documentary films that bring much needed
attention to the plight of those with limited or no access to
healthcare.
27. 26
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
BHI Charitable Foundation: Gala Photos
28. 27
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Patient Testimonials With Video Links
“I was injured 20 years ago. I was in a
car accident driving to Florida with
some friends. My injury, C4, C5
incomplete, which means from the
chest down there's no movement...I do
believe that these stem cells are going
to make a big change. At least, in my
body, I've seen it, I'm very happy with
the progress because every time, it's
something new. Every time.”
Yesenia Torres, 45 years old
“ My twins were nine months old
when I was injured. So you miss a
lot of things if you're not able to get
on the floor and play with them -
really interact with them. Basically,
it gave me my life back.”
Jeremy Hogan, 40 years old
"I was severely injured in a car
accident. My car lost control and hit a
telephone pole. The whole transmission
went into my leg, which almost led to
amputation. After limb saving surgery,
Dr. Mehling introduced me to stem cells.
Soon, I felt the strength returning to my
calf muscle and started walking better. I
am on my back to living a normal life -
walking, driving, playing sports.”
David Berger, 26 years old
*Click pictures to view online video of testimonial ** Additional videos, click here: bluehorizonstemcells.com
29. 28
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
US Affiliate Company: BHI
Therapeutic Sciences
Overview of BHI’s expansion into the US Market
5. US Affiliate Company BHI Therapeutics Sciences
30. 29
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
BHI Therapeutic Sciences: Corporate Overview
BHI Therapeutic Sciences is opening up clinics across the US, where
they will be conducting FDA clinical trials in various indications based
on the research from the international business’s patients.
The company is also marketing a line of skin care products utilizing
the stem cell technology, Alpha Blu.
BHI Therapeutic
Sciences was formed
to capitalize on the
progress made by
the international
business and expand
into the US Market
31. 30
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
BHI Therapeutic Sciences Efforts to Date
Clinic Locations:
New Jersey clinic is already established and prepared to
perform trial procedures
Planning to expand to Texas in order to take advantage
of legislation that allows a profit on research subjects
participating in clinical trials. Targeting late 2019, early
2021 for launch and planning to charge $10,000 per dose
for the procedures
BHI Successful Research Treatments:
100 research subjects with chronic inflammation
30 patients with spinal cord injury
97 research stroke patients
350 research subjects with musculoskeletal disorders
Regulatory Compliance Consulting Company:
• Signed contract with a Fortune 100 multinational
healthcare company which will oversee each trial
32. 31
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Stroke and follow-on FDA trials
Have FDA approval to start Phase I trial
Primary objective: evaluate the safety of Hematopoietic
Stem Cells (HPC), Cord Blood in subjects with acute
ischemic stroke
Secondary objective: evaluate the efficacy of HPC,
Cord Blood in subjects with acute ischemic stroke
Study starts with 10 research subjects, will then attempt
to get approval for more
Obtained approval to charge cost of dose, cannot
charge profit. Estimated charge will be $5,000 per dose
Three therapy sessions per research subject
ClinicalTrials.gov Identifier: NCT03735277
The ability to charge subjects participating in
clinical trials offsets the overall cost of
obtaining FDA approval.
Stroke FDA Trial
Third priority
Could be completed quickly
Study starts with 10 research subjects
Stating timeline of 3 – 6 months
Three therapy sessions per research subject
Diabetes Trial
Planned trial following stroke trial
Study starts with 10 research subjects
Starting timeline of 3 - 6 months
One therapy per research subject
May be able to start receiving
insurance reimbursement for
procedure
Knee Osteoarthritis Associated Pain Trial
Additional trials to follow
Follow-on trials
33. 32
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Cosmetic skin care line,
produced in Germany
Contains more than 32 cytokines
and growth factors derived from
our human stem cell cultures
BHI purchases Alpha Blu
products from affiliated entity
75% gross margins
Plan to partner with drop
shipper
What is Alpha Blu?
Purpose is to evaluate the safety and efficacy of the product
Stimulation of the natural skin production of elastin and collagen
Leads to a dramatic reduction in oxidative stress
Developed sunscreen that does not contain any cancer-causing chemicals
Market could include balm to reduce scarring and stretch marks, and be used
for psoriasis
Research
Approved by the Institutional Review Board
Safety Study of Alpha Blu Skin Care Line Application for Skin Anti-
Aging (IRCM-2017-140, February 22, 2017)
Safety Study of Post-Surgical Balm Application for Scar Reduction
(IRCM-2016-107, May 25, 2016)
Research Studies in Wound Healing and Skin Rejuvenation
Kit contains four products, costs $349
(day, night, eye, and skin creams)
Individual bottles: eye cream, $72,
smoothing skin serum, $99; day cream,
$124; night cream, $124
Variety of combination kits at different
price points
Discount codes are promoted
Alpha Blu Pricing Alpha Blu Distribution
Product being marketed to dermatology practices
Sold direct to consumers via
www.alphabluskincare.com
Also sold on Amazon
Promoted on social media
Currently moving website to Shopify platform for
better social media integration
(1) https://www.marketwatch.com/press-release/stem-cells-market-size-is-projected-to-be-around-us-297-billion-by-2022-2018-06-19
(2) https://www.healthline.com/health/stem-cell-research
Alpha Blu
34. 33
For Prospective Professional Investors/Qualified Investors only – Proprietary & Confidential
Financial Projections
1Based on estimated corporate tax
rate and customary treatment of
tax-loss carry forward
2EBITDA is not generally
considered GAAP accounting
Note: Projections are dependent
upon reasonably timed funding,
relate to future performance, and
reflect expectations at the time this
presentation was prepared.
Projections are subject to risks,
uncertainties, and assumptions
that may cause these projections to
differ materially from the actual
results. We can provide no
assurance that these expectations
will prove to be correct and these
financial projections should not be
unduly relied upon.
BHI Therapeutic Sciences, Inc. 2020 2021 2022 2023 2024
(projected) (projected) (projected) (projected) (projected)
Revenue
Revenue from Alpha Blue 499,338$ 753,844$ 916,302$ 1,113,770$ 1,353,795$
Revenue from Proceedures 1,950,000$ 6,800,000$ 7,260,000$ 9,750,728$ 17,363,628$
Total Revenue 2,449,338$ 7,553,844$ 8,176,302$ 10,864,498$ 18,717,423$
Costs & Expenses
Cost of Goods Sold 2,042,457$ 3,513,077$ 3,767,445$ 5,042,429$ 8,884,883$
General & Administrative 316,025$ 549,872$ 448,710$ 564,136$ 733,132$
Marketing 139,230$ 203,847$ 298,452$ 436,963$ 639,758$
Depreciation & Amortization 17,500$ 65,733$ 59,402$ 53,681$ 48,511$
R&D 129,304$ 157,170$ 191,041$ 232,211$ 282,254$
Total Cost & Expenses 2,644,516$ 4,489,698$ 4,765,050$ 6,329,421$ 10,588,538$
Income from Operation (195,179)$ 3,064,146$ 3,411,252$ 4,535,077$ 8,128,885$
Pre-tax Income (195,179)$ 3,064,146$ 3,411,252$ 4,535,077$ 8,128,885$
Provision for Income Tax1
-$ 803,311$ 955,151$ 1,269,822$ 2,276,088$
Net Income (195,179)$ 2,260,835$ 2,456,101$ 3,265,256$ 5,852,797$
EBITDA
2
(177,679)$ 3,129,879$ 3,470,654$ 4,588,758$ 8,177,396$
$(5,000,000)
$-
$5,000,000
$10,000,000
$15,000,000
$20,000,000
2020 2021 2022 2023 2024
Total Revenue
EBITDA
Net Income